Comparative Genomics of the Major Parasitic Worms

Total Page:16

File Type:pdf, Size:1020Kb

Comparative Genomics of the Major Parasitic Worms Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................. 16 2.2 Data production, McDonnell Genome Institute (MGI) .............................................................................. 18 Genome sequencing library preparation ...................................................................................................... 18 Genome assembly ........................................................................................................................................ 19 Assembly QC / Contamination screening ..................................................................................................... 20 Transcriptome sequencing and assembly .................................................................................................... 20 Gene prediction ............................................................................................................................................ 20 2.3 Data production, Blaxter Nematode and Neglected Genomics (BaNG) .................................................... 21 Genome sequencing library preparation and sequencing ........................................................................... 21 Genome assembly ........................................................................................................................................ 22 Assembly QC ................................................................................................................................................. 22 Gene prediction ............................................................................................................................................ 22 3 Functional annotation ................................................................................................................................... 22 Assigning protein names to predicted proteins............................................................................................ 22 Assigning GO terms to predicted proteins ................................................................................................... 23 4 Repeat libraries and repeat-masking ............................................................................................................ 24 5 Regression model for genome size ............................................................................................................... 25 6 Mitochondrial genome analysis .................................................................................................................... 26 7 Defining high-quality ‘tier 1’ species for downstream analyses ................................................................... 26 8 Compara database of gene families .............................................................................................................. 27 Construction of the in-house Compara database ........................................................................................ 27 Identification of gene families, orthologs and paralogs .............................................................................. 28 1 9 Identification of synapomorphic gene families ............................................................................................. 28 10 Phylogenetic analysis of candidate lateral gene transfers .......................................................................... 28 11 Network representation of gene families ................................................................................................... 29 12 Phylogenetic tree based on gene family presence/absence ...................................................................... 29 13 Identification of gene family expansions .................................................................................................... 29 14 Species Tree ................................................................................................................................................. 32 15 Novel domain combinations ....................................................................................................................... 32 16 Ion Channels and ABC Transporters ............................................................................................................ 33 17 Proteases ..................................................................................................................................................... 33 18 Kinase prediction ......................................................................................................................................... 33 20 Signal peptide for secretion and TM domains predictions ......................................................................... 34 21 InterPro and GO annotations ...................................................................................................................... 34 22 Species-level functional enrichment (GO / InterPro / Pfam) analysis ........................................................ 34 23 SCP/TAPS protein family ............................................................................................................................. 34 24 GPCR analysis .............................................................................................................................................. 35 25 Metabolism ................................................................................................................................................. 36 Assigning ECs to predicted proteins and generating high-confidence EC predictions ................................. 36 Reconstructing metabolic pathways and pathway hole-filling .................................................................... 37 Analysis of KEGG metabolic modules and pathways ................................................................................... 37 Analysis of chokepoints in metabolic pathways ........................................................................................... 38 Carbohydrate active enzymes (CAZymes) .................................................................................................... 39 26 Identification of Potential Anthelmintic Drug Targets and Drugs............................................................... 39 Known anthelmintic drugs and compounds ................................................................................................. 39 Dendrogram of known anthelmintic compounds......................................................................................... 40 Identifying potential helminth drug targets ................................................................................................. 40 Identifying potential new anthelmintic drugs in ChEMBL ............................................................................ 44 Diversity analysis for creating a ‘diverse screening set’ ............................................................................... 45 Identifying compounds available for purchase using ZINC15 ...................................................................... 46 Self-organising map of compounds .............................................................................................................. 47 Supplementary Results .............................................................................................................. 48 1. Genomic diversity in parasitic nematodes and platyhelminths ................................................... 48 1.1 Genome sequencing and assembly ............................................................................................................ 48 Sequencing strategy ..................................................................................................................................... 48 Genome assembly pipeline validation .......................................................................................................... 48 Assembly statistics ......................................................................................................................................
Recommended publications
  • Full Text in Pdf Format
    DISEASES OF AQUATIC ORGANISMS Published July 30 Dis Aquat Org Oral pharmacological treatments for parasitic diseases of rainbow trout Oncorhynchus mykiss. 11: Gyrodactylus sp. J. L. Tojo*, M. T. Santamarina Department of Microbiology and Parasitology, Laboratory of Parasitology, Faculty of Pharmacy, Universidad de Santiago de Compostela, E-15706 Santiago de Compostela, Spain ABSTRACT: A total of 24 drugs were evaluated as regards their efficacy for oral treatment of gyro- dactylosis in rainbow trout Oncorhj~nchusmykiss. In preliminary trials, all drugs were supplied to infected fish at 40 g per kg of feed for 10 d. Twenty-two of the drugs tested (aminosidine, amprolium, benznidazole, b~thionol,chloroquine, diethylcarbamazine, flubendazole, levamisole, mebendazole, n~etronidazole,mclosamide, nitroxynil, oxibendazole, parbendazole, piperazine, praziquantel, roni- dazole, secnidazole, tetramisole, thiophanate, toltrazuril and trichlorfon) were ineffective Triclabenda- zole and nitroscanate completely eliminated the infection. Triclabendazole was effective only at the screening dosage (40 g per kg of feed for 10 d), while nitroscanate was effective at dosages as low as 0.6 g per kg of feed for 1 d. KEY WORDS: Gyrodactylosis . Rainbow trout Treatment. Drugs INTRODUCTION to the hooks of the opisthohaptor or to ulceration as a result of feeding by the parasite. The latter is the most The monogenean genus Gyrodactylus is widespread, serious. though some individual species have a restricted distri- Transmission takes place largely as a result of direct bution. Gyrodactyloses affect numerous freshwater contact between live fishes, though other pathways species including salmonids, cyprinids and ornamen- (contact between a live fish and a dead fish, or with tal fishes, as well as marine fishes including gadids, free-living parasites present in the substrate, or with pleuronectids and gobiids.
    [Show full text]
  • Comparative Efficacies of Commercially Available Benzimidazoles Against Pseudodactylogyrus Infestations in Eels
    DISEASES OF AQUATIC ORGANISMS Published October 4 Dis. aquat. Org. l Comparative efficacies of commercially available benzimidazoles against Pseudodactylogyrus infestations in eels ' Department of Fish Diseases, Royal Veterinary and Agricultural University, 13 Biilowsvej, DK-1870 Frederiksberg C, Denmark Department of Pharmacy, Royal Veterinary and Agricultural University, 13 Biilowsvej. DK-1870 Frederiksberg C,Denmark ABSTRACT: The antiparasitic efficacies of 9 benzimidazoles in commercially avalable formulations were tested (water bath treatments) on small pigmented eels Anguilla anguilla, expenmentally infected by 30 to 140 specimens of Pseudodactylogyrus spp. (Monogenea).Exposure time was 24 h and eels were examined 4 to 5 d post treatment. Mebendazole (Vermox; 1 mg 1-') eradicated all parasites, whereas luxabendazole (pure substance) and albendazole (Valbazen) were 100 % effective only at a concen- tration of 10 mg I-'. Flubendazole (Flubenol), fenbendazole (Panacur) and oxibendazole (Lodltac) (10 mg l-') caused a reduction of the infection level to a larger extent than did triclabendazole (Fasinex) and parbendazole (Helmatac).Thiabendazole (Equizole), even at a concentration as high as 100 mg l-', was without effect on Pseudodactylogyrus spp. INTRODUCTION range of commercially available benzimidazole com- pounds. If drug resistance will develop under practical The broad spectrum anthelmintic drug mebendazoIe eel-farm conditions in the future, it is likely to be was reported as an efficacious compound against infes- recognized during treatments with commercially avail- tations of the European eel Anguilla anguilla with gill able drug formulations. Therefore this type of drug parasitic monogeneans of the genus Pseudodactylo- preparations were used in the present study. gyms (Szekely & Molnar 1987, Buchmann & Bjerre- gaard 1989, 1990, Mellergaard 1989).
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,861,142 Schick (45) Date of Patent: *Jan
    USOO586 1142A United States Patent (19) 11 Patent Number: 5,861,142 Schick (45) Date of Patent: *Jan. 19, 1999 54 METHOD FOR PROMOTING HAIR, NAIL, 0 090 368 10/1983 European Pat. Off.. AND SKIN KERATINIZATION 0 187 012 7/1986 European Pat. Off.. 0 224 249 6/1987 European Pat. Off.. 76 Inventor: Mary Pichler Schick, 2027 Old Forge b 5. g i. As E. Way, Marietta, Ga. 30068 0 0 W.e "9CO * Notice: This patent issued on a continued pros- 95/16447 6/1995 WIPO. ecution application filed under 37 CFR OTHER PUBLICATIONS 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. Biochemistry Pharm., The interaction of benzimidazole Cat 154(a)(2). bamates with mammalian microtobule protein Vol. 28, p. 268O-2682. Davidse and Flach, “Differential Binding of Methyl 21 Appl. No.: 621,473 Benzimidazol-2-yl Carbamate to Fungal iustin S y 22 Filed: Mar. 25, 1996 Mechanism of Resistance to this Antimitotic Agent in 6 Mutant Strains of Aspergillus Nidulans”, Journal of Cell 51 Int. Cl. ....................................................... A61K 7/06 Biology, vol. 72, 1977, pp. 174-193. 52 U.S. Cl. ............................ 424/61; 424/701; 424/451; Fisher, et. al., “Efficacy of fenbenzalole and piperazine 424/464; 424/484; 424/489; 514/365; 514/395; against developing Stages of toxocara and toxascaris in 514/937; 514/944 dogs”, The Veterinary Record, vol. 132, No. 19, May 8, 58 Field of Search ..................................... 424/401, 701, 1943, pp. 473–475. 424/451, 464, 484, 489; 514/365, 395, 937, 944 (List continued on next page.) Primary Examiner Jvothsna Venkat 56) References Cited AOC, Agent, Or E".
    [Show full text]
  • Expert Review 2
    2021 Expert Committee on Selection and Use of Essential Medicines Application review I.1 Albendazole, mebendazole and praziquantel for the indication of treatment of (item number) taeniid cestode cysts Does the application adequately ☒ Yes address the issue of the public health ☐ need for the medicine? No ☐ Not applicable Comments: The larval stages of three taeniid cestode parasites, Echinococcus granulosus, Echinococcus multilocularis and Taenia solium, produce cysts in humans that are of medical relevance. The diseases caused by these parasitic cysts are called cystic echinococcosis (CE), alveolar echinococcosis (AE), and cysticercosis (being neurocysticercosis (NCC) the most common form) respectively, and they are recognised by WHO as neglected tropical diseases. NCC is mainly a disease of poverty that predominantly affects rural populations in Africa, Asia and Latin America. Access to diagnostic and treatment, to better manage epilepsy and other NCC is a challenge for the people affected in these communities due to the availability and costs of specialised diagnostic and care. Stigma and social discrimination also mean that many people try to “hide” the disease. Briefly summarize the role of the The only real options for treatment of CE are albendazole (ALB) and Mebendazole proposed medicine(s) relative to other (MEB). ALB is the drug of choice as it has better bioavailability. ALB is also preferred to therapeutic agents currently included in MEB, because MEB requires a higher dose and a higher pill burden, for example, an the Model List, or available in the adult patient would require 8 tablets/day of MEB compared with 2 tablets/day ALB. market. ALB and praziquantel ( PZQ) are the only drugs used for the antiparasitic treatment of NCC.
    [Show full text]
  • ALBENDAZOLE (Extrapolation to All Ruminants)
    European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/865/03-FINAL June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE ALBENDAZOLE (Extrapolation to all ruminants) SUMMARY REPORT (3) 1. Albendazole is a benzimidazole carbamate, used for the treatment of gastrointestinal infestations with roundworms, lungworms and tapeworms and adult flukes of Fasciola hepatica. Albendazole is currently entered into Annex I of Council Regulation (EEC) No. 2377/90 in accordance with the following table: Pharmacologically Marker residue Animal MRLs Target Other active substance(s) species tissues provisions Albendazole Sum of albendazole Bovine, 100 µg/kg Muscle sulphoxide, ovine 100 µg/kg Fat albendazole sulphone 1000 µg/kg Liver and albendazole 2- 500 µg/kg Kidney amino sulphone 100 µg/kg Milk expressed as albendazole 2. In reviewing the availability of endo- and ectoparasiticides for sheep and goats, albendazole was considered for extrapolation from bovine and ovine species to all ruminants. The considerations and criteria leading to the identification of albendazole are described in the Position Paper Regarding Availability of Veterinary Medicines – Extrapolation of MRLs (EMEA/CVMP/457/03-FINAL). 3. The scientific justification for this extrapolation was assessed in accordance with the Notes for Guidance on Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin (EMEA/CVMP/187/00-FINAL) and on the Establishment of Maximum Residue Limits for Minor Animal Species (EMEA/CVMP/153a/97-FINAL). 4. In setting the ADI in the original assessment of albendazole, the data summarised on the paragraphs below were considered. 5. The mode of action of albendazole is by binding strongly with the tubulin in the cells of nematodes.
    [Show full text]
  • Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study
    Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Seq2pathway Vignette
    seq2pathway Vignette Bin Wang, Xinan Holly Yang, Arjun Kinstlick May 19, 2021 Contents 1 Abstract 1 2 Package Installation 2 3 runseq2pathway 2 4 Two main functions 3 4.1 seq2gene . .3 4.1.1 seq2gene flowchart . .3 4.1.2 runseq2gene inputs/parameters . .5 4.1.3 runseq2gene outputs . .8 4.2 gene2pathway . 10 4.2.1 gene2pathway flowchart . 11 4.2.2 gene2pathway test inputs/parameters . 11 4.2.3 gene2pathway test outputs . 12 5 Examples 13 5.1 ChIP-seq data analysis . 13 5.1.1 Map ChIP-seq enriched peaks to genes using runseq2gene .................... 13 5.1.2 Discover enriched GO terms using gene2pathway_test with gene scores . 15 5.1.3 Discover enriched GO terms using Fisher's Exact test without gene scores . 17 5.1.4 Add description for genes . 20 5.2 RNA-seq data analysis . 20 6 R environment session 23 1 Abstract Seq2pathway is a novel computational tool to analyze functional gene-sets (including signaling pathways) using variable next-generation sequencing data[1]. Integral to this tool are the \seq2gene" and \gene2pathway" components in series that infer a quantitative pathway-level profile for each sample. The seq2gene function assigns phenotype-associated significance of genomic regions to gene-level scores, where the significance could be p-values of SNPs or point mutations, protein-binding affinity, or transcriptional expression level. The seq2gene function has the feasibility to assign non-exon regions to a range of neighboring genes besides the nearest one, thus facilitating the study of functional non-coding elements[2]. Then the gene2pathway summarizes gene-level measurements to pathway-level scores, comparing the quantity of significance for gene members within a pathway with those outside a pathway.
    [Show full text]
  • Chemotherapy of Gastrointestinal Helminths
    Chemotherapy of Gastrointestinal Helminths Contributors J. H. Arundel • J. H. Boersema • C. F. A. Bruyning • J. H. Cross A. Davis • A. De Muynck • P. G. Janssens • W. S. Kammerer IF. Michel • M.H. Mirck • M.D. Rickard F. Rochette M. M. H. Sewell • H. Vanden Bossche Editors H. Vanden Bossche • D.Thienpont • P.G. Janssens UNIVERSITATS- BlfiUOTHElC Springer-Verlag Berlin Heidelberg New York Tokyo Contents CHAPTER 1 Introduction. A. DAVIS A. Pathogenic Mechanisms in Man 1 B. Modes of Transmission 2 C. Clinical Sequelae of Infection 3 D. Epidemiological Considerations 3 E. Chemotherapy 4 F. Conclusion 5 References 5 CHAPTER 2 Epidemiology of Gastrointestinal Helminths in Human Populations C. F. A. BRUYNING A. Introduction 7 B. Epidemiological or "Mathematical" Models and Control 8 C. Nematodes 11 I. Angiostrongylus costaricensis 11 II. Anisakis marina 12 III. Ascaris lumbricoides 14 IV. Capillaria philippinensis 21 V. Enterobius vermicularis 23 VI. Gnathostoma spinigerum 25 VII. Hookworms: Ancylostoma duodenale and Necator americanus . 26 VIII. Oesophagostoma spp 32 IX. Strongyloides stercoralis 33 X. Ternidens deminutus 34 XI. Trichinella spiralis 35 XII. Trichostrongylus spp 38 XIII. Trichuris trichiura 39 D. Trematodes 41 I. Echinostoma spp 41 II. Fasciolopsis buski 42 III. Gastrodiscoides hominis 44 IV. Heterophyes heterophyes 44 V. Metagonimus yokogawai 46 X Contents E. Cestodes 47 I. Diphyllobothrium latum 47 II. Dipylidium caninum 50 III. Hymenolepis diminuta 51 IV. Hymenolepis nana 52 V. Taenia saginata 54 VI. Taenia solium 57 VII. Cysticercosis cellulosae 58 References 60 CHAPTER 3 Epidemiology and Control of Gastrointestinal Helminths in Domestic Animals J. F. MICHEL. With 20 Figures A. Introduction 67 I.
    [Show full text]
  • Lecture 5: Emerging Parasitic Helminths Part 2: Tissue Nematodes
    Readings-Nematodes • Ch. 11 (pp. 290, 291-93, 295 [box 11.1], 304 [box 11.2]) • Lecture 5: Emerging Parasitic Ch.14 (p. 375, 367 [table 14.1]) Helminths part 2: Tissue Nematodes Matt Tucker, M.S., MSPH [email protected] HSC4933 Emerging Infectious Diseases HSC4933. Emerging Infectious Diseases 2 Monsters Inside Me Learning Objectives • Toxocariasis, larva migrans (Toxocara canis, dog hookworm): • Understand how visceral larval migrans, cutaneous larval migrans, and ocular larval migrans can occur Background: • Know basic attributes of tissue nematodes and be able to distinguish http://animal.discovery.com/invertebrates/monsters-inside- these nematodes from each other and also from other types of me/toxocariasis-toxocara-roundworm/ nematodes • Understand life cycles of tissue nematodes, noting similarities and Videos: http://animal.discovery.com/videos/monsters-inside- significant difference me-toxocariasis.html • Know infective stages, various hosts involved in a particular cycle • Be familiar with diagnostic criteria, epidemiology, pathogenicity, http://animal.discovery.com/videos/monsters-inside-me- &treatment toxocara-parasite.html • Identify locations in world where certain parasites exist • Note drugs (always available) that are used to treat parasites • Describe factors of tissue nematodes that can make them emerging infectious diseases • Be familiar with Dracunculiasis and status of eradication HSC4933. Emerging Infectious Diseases 3 HSC4933. Emerging Infectious Diseases 4 Lecture 5: On the Menu Problems with other hookworms • Cutaneous larva migrans or Visceral Tissue Nematodes larva migrans • Hookworms of other animals • Cutaneous Larva Migrans frequently fail to penetrate the human dermis (and beyond). • Visceral Larva Migrans – Ancylostoma braziliense (most common- in Gulf Coast and tropics), • Gnathostoma spp. Ancylostoma caninum, Ancylostoma “creeping eruption” ceylanicum, • Trichinella spiralis • They migrate through the epidermis leaving typical tracks • Dracunculus medinensis • Eosinophilic enteritis-emerging problem in Australia HSC4933.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Dr. Donald L. Price Center for Parasite Repository and Education College of Public Health, University of South Florida
    Dr. Donald L. Price Center For Parasite Repository and Education College of Public Health, University of South Florida PRESENTS Sources of Infective Stages and Modes of Transmission of Endoparasites Epidemiology is the branch of science that deals with the distribution and spread of disease. How diseases are transmitted, i.e. how they are passed from an infected individual to a susceptible one is a major consideration. Classifying and developing terminology for what takes place has been approached in a variety of ways usually related to specific disease entities such as viruses, bacteria, etc. The definitions that follow apply to those disease entities usually classified as endoparasites i.e. those parasites that reside in a body passage or tissue of the definitive host or in some cases the intermediate host. When the definition of terms for the “Source of Infection” or “Mode of Infection” relate to prevention and/or control of an endoparasitic disease, they should be clearly described. For the source of infection, the medium (water, soil, utensils, etc.) or the host organism (vector, or intermediate host) on which or in which the infective stage can be found should be precisely identified. For the mode of transmission, the precise circumstances and means by which the infective stage is able to come in contact with, enter, and initiate an infection in the host should be described. SOURCE OF INFECTION There are three quite distinct and importantly different kinds of sources of the infective stage of parasites: Contaminated Sources, Infested Sources, and Infected Sources. CONTAMINATE SOURCES Contaminated Source, in parasitology, implies something that has come in contact with raw feces and is thereby polluted with feces or organisms that were present in it.
    [Show full text]